Controlling transgene expression in subcutaneous implants using a skin lotion containing the apple metabolite phloretin Adjustable control of therapeutic transgenes in engineered cell implants after transdermal and topical delivery of nontoxic trigger molecules would increase convenience, patient compliance, and elimination of hepatic first-pass effect in future therapies.
